NCT02079740: Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02079740
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: RAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have KRAS+ or NRAS+ tumor mutations
Exclusions: Patients with known brain metastases
https://ClinicalTrials.gov/show/NCT02079740

Comments are closed.

Up ↑